High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India = High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India

다국어 초록 (Multilingual Abstract)

Background/Aims: The data on the risk of tuberculosis (TB) reactivation with infliximab (IFX) in patients with inflammatory bowel disease (IBD) from TB endemic countries, like India, is limited. The risk of TB reactivation on IFX and its predictors in patients with IBD was assessed. Methods: This retrospective review included consecutive patients with IBD who received IFX, and were on follow-up from January 2005 to November 2017. The data was recorded on age/disease duration, indications for IFX, screening for latent tuberculosis (LTB) before IFX, response to IFX, incidence and duration when TB developed after IFX, and type of TB (pulmonary [PTB]/extra-pulmonary [EPTB]/disseminated). Results: Of 69 patients (22 ulcerative colitis/47 Crohn’s disease; mean age, 35.6±14.5 years; 50.7% males; median follow-up duration after IFX, 19 months [interquartile range, 5.5-48.7 months]), primary non-response at 8 weeks and secondary loss of response at 26 and 52 weeks were seen in 14.5%, 6% and 15% patients respectively. Prior to IFX, all patients were screened for LTB, 8 (11.6%) developed active TB (disseminated, 62.5%; EPTB, 25%; PTB, 12.5%) after a median of 19 weeks (interquartile range, 14.0-84.5 weeks) of IFX. Of these 8 patients’ none had LTB, even when 7 of 8 were additionally screened with contrast-enhanced chest tomography. Though not statistically significant, more patients with Crohn’s disease than ulcerative colitis (14.9% vs. 4.5%, P=0.21), and those with past history of TB (25% vs. 9.8%, P=0.21), developed TB. Age, gender, disease duration, or extraintestinal manifestations could not predict TB reactivation. Conclusions: There is an extremely high rate of TB with IFX in Indian patients with IBD. Current screening techniques are ineffective and it is difficult to predict TB after IFX. (Intest Res 2018;16:588-598)

참고문헌 (Reference)

1 Baron JH, "Variation between observers in describing mucosal appearances in proctocolitis" 1 : 89-92, 1964

2 Debeuckelaere C, "Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening" 8 : 550-557, 2014

3 Abreu C, "Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population" 7 : e486-e492, 2013

4 "Treatment of tuberculosis: guidelines. Case definitions" NCBI

5 Gomez-Reino JJ, "Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report" 48 : 2122-2127, 2003

6 Silverberg MS, "Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology" 19 (19): 5A-36A, 2005

7 Van Assche G, "The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis" 4 : 7-27, 2010

8 Roach DR, "TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection" 168 : 4620-4627, 2002

9 Makharia GK, "Survey of inflammatory bowel diseases in India" 31 : 299-306, 2012

10 Kim ES, "Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents" 21 : 3308-3316, 2015

11 김경희, "Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents" 대한진단검사의학회 31 (31): 271-278, 2011

12 Dignass A, "Second European evidence- based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis" 6 : 965-990, 2012

13 Chen-Wang Chang, "Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn’s Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study" 대한장연구학회 12 (12): 287-292, 2014

14 Byun JM, "Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor" 50 : 312-320, 2015

15 Tubach F, "Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry" 60 : 1884-1894, 2009

16 Tam LS, "Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong: the role of TNF blockers in an area of high tuberculosis burden" 679-685, 2010

17 Jung SM, "Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden" 18 : 323-330, 2015

18 Jauregui-Amezaga A, "Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening" 7 : 208-212, 2013

19 Prashant Singh, "Pivot to Asia: inflammatory bowel disease burden" 대한장연구학회 15 (15): 138-141, 2017

20 Abitbol Y, "Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort" 10 : 1179-1185, 2016

21 Fallahi-Sichani M, "Multiscale computational modeling reveals a critical role for TNF-alpha receptor 1 dynamics in tuberculosis granuloma formation" 186 : 3472-3483, 2011

22 "Latent TB infection: updated and consolidated guidelines for programmatic management" WHO

23 Getahun H, "Latent Mycobacterium tuberculosis infection" 372 : 2127-2135, 2015

24 Mack U, "LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement" 33 : 956-973, 2009

25 Anibarro L, "Interferon-gamma release assays in tuberculosis contacts: is there a window period?" 37 : 215-217, 2011

26 Hsia EC, "Interferon-$\gamma$ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis" 64 : 2068-2077, 2012

27 Puri AS, "Infliximab-induced tuberculosis in patients with UC: experience from India-a country with high prevalence of tuberculosis" 32 : 1191-1194, 2017

28 Sood A, "Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience" 33 : 31-34, 2014

29 Ahuja V, "Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences" 11 : 134-147, 2010

30 Wallis RS, "Granulomatous infectious diseases associated with tumor necrosis factor antagonists" 38 : 1261-1265, 2004

31 "Global tuberculosis report 2017"

32 Lee J, "Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist" 14 : 690-697, 2017

33 Yildirim Z, "Effects of the Health Transformation Programme on tuberculosis burden in Turkey" 107 : 2029-2037, 2013

34 Carmona L, "Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists" 52 : 1766-1772, 2005

35 Dixon WG, "Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)" 69 : 522-528, 2010

36 Liao TL, "Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan" 11 : e0153217-, 2016

37 Best WR, "Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study" 70 : 439-444, 1976

38 Truelove SC, "Cortisone in ulcerative colitis; preliminary report on a therapeutic trial" 2 : 375-378, 1954

39 Kisacik B, "Characteristics predicting tuberculosis risk under tumor necrosis factor-alpha inhibitors: report from a large multicenter cohort with high background prevalence" 43 : 524-529, 2016

40 Chen DY, "Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF-alpha inhibitors: the utility of IFNgamma assay" 71 : 231-237, 2012

41 Dong Il Park, "Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management" 대한장연구학회 16 (16): 17-25, 2018

42 Dong Il Park, "Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment" 대한장연구학회 16 (16): 4-16, 2018

43 Walmsley RS, "A simple clinical colitis activity index" 43 : 29-32, 1998

44 Sandborn WJ, "A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease" 122 : 512-530, 2002